Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGN-352 in Acute STEMI
NCT01311518Phase 2Withdrawn
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of thymosin beta-4 in ST elevation myocardial infarction (STEMI), sponsored by RegeneRx Biopharmaceuticals, Inc.. Planned start Jul 2019; status: withdrawn.
02
Drugs
thymosin beta-4
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01311518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01311518.